Question

Al. Efficacy and safety of a 41. Novartis oncology, the glivec international site. Aboutspecific inhibitor of the bcr-abl tyrosine kinase in chronic glivec: [european] summary of product characteristics [onmyeloidleukemia.

Answer 1

from which chapter this is from

Answer 2

bro what is this..

of which class is this question..

unable to understand..

sorry.. can't help u..